5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

被引：21

作者：

Federici, Laetitia ^{[1
]}

Capelle, Laurent ^{[2
]}

Annereau, Maxime ^{[1
]}

Bielle, Franck ^{[3
]}

Willekens, Christophe ^{[4
,5
]}

Dehais, Caroline ^{[6
]}

Laigle-Donadey, Florence ^{[6
]}

Hoang-Xuan, Khe ^{[6
]}

Delattre, Jean-Yves ^{[6
]}

Idbaih, Ahmed ^{[6
]}

Lemare, Francois ^{[1
]}

de Botton, Stephane ^{[4
,5
]}

Sanson, Marc ^{[6
]}

Touat, Mehdi ^{[6
,7
]}

机构：

[1] Paris Saclay Univ, Pharm Clin Serv, Gustave Roussy Canc Campus, Villejuif, France

[2] Univ Hosp Pitie Salpetriere Charles Foix, Dept Neurosurg, Paris, France

[3] Sorbonne Univ, Inst Brain & Spinal Cord, Dept Neurosurg, Univ Hosp Pitie Salpetriere Charles Foix,Neuropat, Paris, France

[4] Univ Paris Saclay, Gustave Roussy, Dept Hematol, F-94805 Villejuif, France

[5] Paris Saclay Univ, INSERM, Unit 1170, Gustave Roussy Canc Campus, Villejuif, France

[6] Sorbonne Univ, Inst Brain & Spinal Cord, Univ Hosp Pitie Salpetriere Charles Foix, Dept Neurosurg,Neurol Serv 2 Mazarin, Paris, France

[7] Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA

来源：

NEURO-ONCOLOGY | 2020年 / 22卷 / 08期

关键词：

CONVENTIONAL CARE REGIMENS; ACUTE MYELOID-LEUKEMIA; OLDER PATIENTS; IDH1; AZACITIDINE; MUTATIONS;

D O I：

10.1093/neuonc/noaa074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1226 / 1228

页数：3

共 10 条

[1] Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature [J].

Craddock, Charles F. ;

Houlton, Aimee E. ;

Quek, Lynn Swun ;

Ferguson, Paul ;

Gbandi, Emma ;

Roberts, Corran ;

Metzner, Marlen ;

Garcia-Martin, Natalia ;

Kennedy, Alison ;

Hamblin, Angela ;

Raghavan, Manoj ;

Nagra, Sandeep ;

Dudley, Louise ;

Wheatley, Keith ;

McMullin, Mary Frances ;

Pillai, Srinivas P. ;

Kelly, Richard J. ;

Siddique, Shamyla ;

Dennis, Michael ;

Cavenagh, Jamie D. ;

Vyas, Paresh .

CLINICAL CANCER RESEARCH, 2017, 23 (21) :6430-6440

[2] Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents [J].

DiNardo, Courtney D. ;

Patel, Keyur P. ;

Garcia-Manero, Guillermo ;

Luthra, Rajyalakshmi ;

Pierce, Sherry ;

Borthakur, Gautam ;

Jabbour, Elias ;

Kadia, Tapan ;

Pemmaraju, Naveen ;

Konopleva, Marina ;

Faderl, Stefan ;

Cortes, Jorge ;

Kantarjian, Hagop M. ;

Ravandi, Farhad .

LEUKEMIA & LYMPHOMA, 2014, 55 (08) :1925-1929

[3] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts [J].

Dombret, Herve ;

Seymour, John F. ;

Butrym, Aleksandra ;

Wierzbowska, Agnieszka ;

Selleslag, Dominik ;

Jang, Jun Ho ;

Kumar, Rajat ;

Cavenagh, James ;

Schuh, Andre C. ;

Candoni, Anna ;

Recher, Christian ;

Sandhu, Irwindeep ;

Bernal del Castillo, Teresa ;

Al-Ali, Haifa Kathrin ;

Martinelli, Giovanni ;

Falantes, Jose ;

Noppeney, Richard ;

Stone, Richard M. ;

Minden, Mark D. ;

McIntyre, Heidi ;

Songer, Steve ;

Lucy, Lela M. ;

Beach, C. L. ;

Doehner, Hartmut .

BLOOD, 2015, 126 (03) :291-299

[4] Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia [J].

Emadi, Ashkan ;

Faramand, Rawan ;

Carter-Cooper, Brandon ;

Tolu, Seda ;

Ford, Laurie A. ;

Lapidus, Rena G. ;

Wetzler, Meir ;

Wang, Eunice S. ;

Etemadi, Arash ;

Griffiths, Elizabeth A. .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) :E77-E79

[5] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Gattermann, Norbert ;

Germing, Ulrich ;

Sanz, Guillermo ;

List, Alan F. ;

Gore, Steven ;

Seymour, John F. ;

Dombret, Herve ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :562-569

[6] IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives [J].

Mondesir, Johanna ;

Willekens, Christophe ;

Touat, Mehdi ;

de Botton, Stephane .

JOURNAL OF BLOOD MEDICINE, 2016, 7 :171-180

[7] Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas [J].

Sanson, Marc ;

Marie, Yannick ;

Paris, Sophie ;

Idbaih, Ahmed ;

Laffaire, Julien ;

Ducray, Francois ;

El Hallani, Soufiane ;

Boisselier, Blandine ;

Mokhtari, Karima ;

Hoang-Xuan, Khe ;

Delattre, Jean-Yves .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4150-4154

[8] Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. [J].

Turcan, Sevin ;

Fabius, Armida W. M. ;

Borodovsky, Alexandra ;

Pedraza, Alicia ;

Brennan, Cameron ;

Huse, Jason ;

Viale, Agnes ;

Riggins, Gregory J. ;

Chan, Timothy A. .

ONCOTARGET, 2013, 4 (10) :1729-1736

[9] IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype [J].

Turcan, Sevin ;

Rohle, Daniel ;

Goenka, Anuj ;

Walsh, Logan A. ;

Fang, Fang ;

Yilmaz, Emrullah ;

Campos, Carl ;

Fabius, Armida W. M. ;

Lu, Chao ;

Ward, Patrick S. ;

Thompson, Craig B. ;

Kaufman, Andrew ;

Guryanova, Olga ;

Levine, Ross ;

Heguy, Adriana ;

Viale, Agnes ;

Morris, Luc G. T. ;

Huse, Jason T. ;

Mellinghoff, Ingo K. ;

Chan, Timothy A. .

NATURE, 2012, 483 (7390) :479-U137

[10] Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide [J].

Yamashita, Alex Shimura ;

Rosa, Marina da Costa ;

Borodovsky, Alexandra ;

Festuccia, William T. ;

Chan, Timothy ;

Riggins, Gregory J. .

NEURO-ONCOLOGY, 2019, 21 (02) :189-200

← 1 →